The Effect of Alfa-Adrenergic Receptor Blockade on Insulin-Stimulated Forearm Glucose Uptake and Metabolism in Chronic Heart Failure

The recruitment status of this study is unknown because the information has not been verified recently.

Verified August 2007 by Radboud University. Recruitment status was Recruiting

First Received on August 18, 2005. Last Updated on August 30, 2007 History of Changes

Sponsor:	Radboud University
Collaborator:	ZonMw: The Netherlands Organisation for Health Research and Development
Information provided by:	Radboud University
ClinicalTrials.gov Identifier:	NCT00132106

Purpose

The activity of the sympathetic nervous system seems to influence the uptake (and handling) of glucose by the skeletal muscle of the forearm. Conditions in which sympathetic activity is increased seem to inhibit/reduce forearm glucose uptake. Inversely a decrease in sympathetic activity seems to increase glucose uptake. This study analyzes the effect of alfa-adrenergic receptor blockade (counteracting sympathetic influence) on insulin-stimulated forearm glucose uptake in patients with increased sympathetic activity (patients with chronic heart failure).

Condition	Intervention
Heart Failure, Congestive	Drug: phentolamine

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label
Official Title:	The Effect of a-Adrenergic Receptor Blockade on Insulin-Stimulated Forearm Glucose Uptake and Metabolism in Chronic Heart Failure

Resource links provided by NLM:

MedlinePlus related topics: Diabetes Medicines Heart Failure

Drug Information available for: Phentolamine Phentolamine mesylate Insulin

U.S. FDA Resources

Further study details as provided by Radboud University:

Primary Outcome Measures:

change in glucose uptake

Study Start Date:

August 2005

Eligibility

Ages Eligible for Study:	18 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Heart failure of at least New York Heart Association (NYHA) class II
Left ventricular ejection fraction (LVEF) <= 40%
Age 18-75 years

Exclusion Criteria:

Alfa-blockers, or beta-blockers with alfa-blocking activity (carvedilol)
Tricyclic antidepressants
Warfarin derivatives (acetylic salicylic acid and clopidogrel are allowed)
Hospitalisation in 6 weeks prior to the study
Any change in medication in 6 weeks prior to the study
Unstable angina
Orthopnoea
Known chronic disease of the autonomic nervous system
Diabetes mellitus
Oedema of the lower extremities, complicating the insertion of a venous catheter in a vein on the foot

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00132106

Contacts

Contact: Marc E.R. Gomes, MD

+31-24-3614533/3616550

m.gomes@cardio.umcn.nl

Locations

Netherlands
Radboud University Nijmegen Medical Centre	Recruiting
Nijmegen, Netherlands, 6500 HB
Contact: Marc ER Gomes, MD 31-24-3614533/3616550 m.gomes@cardio.umcn.nl
Sub-Investigator: Marc ER Gomes, MD
Sub-Investigator: Alexandra H Mulder, MD
Sub-Investigator: Freek WA Verheugt, MD, PhD
Sub-Investigator: Paul Smits, MD, PhD
Principal Investigator: Cees J Tack, MD, PhD
Sub-Investigator: Louise Bellersen, MD

Sponsors and Collaborators

Radboud University

ZonMw: The Netherlands Organisation for Health Research and Development

Investigators

Principal Investigator:

Cees J Tack, MD, PhD

Radboud University

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00132106 History of Changes
Other Study ID Numbers:	CHFALFA
Study First Received:	August 18, 2005
Last Updated:	August 30, 2007
Health Authority:	Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Additional relevant MeSH terms:

Heart Failure
Heart Diseases
Cardiovascular Diseases
Adrenergic Agents
Phentolamine
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

Pharmacologic Actions
Physiological Effects of Drugs
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Adrenergic alpha-Antagonists
Adrenergic Antagonists

ClinicalTrials.gov processed this record on February 13, 2012